Atlas Trials

Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment

Clinical trial NCT04438902 · TERMINATED

Trial details

NCT number
NCT04438902
Sponsor
First Affiliated Hospital of Zhejiang University
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2020-12-12
Primary completion
2022-12-08
Enrollment
3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.